Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sasanlimab - Pfizer

X
Drug Profile

Sasanlimab - Pfizer

Alternative Names: PF-06801591; PF-6801591; RN-888

Latest Information Update: 17 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bladder cancer
  • Phase II Renal cell carcinoma
  • Phase I/II Non-small cell lung cancer; Solid tumours
  • Discontinued Lymphoma

Most Recent Events

  • 10 Jan 2025 Efficacy and adverse event data from phase III CREST trial for Bladder cancer released by Pfizer
  • 06 Nov 2024 Pfizer terminates phase-I clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Puerto Rico, USA (SC) (NCT06448364)
  • 01 Nov 2024 Pfizer initiates enrolment in a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (SC, Injection) (NCT06580938)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top